Search results for "LIVER TRANSPLANTATION"

showing 10 items of 359 documents

Comparative analysis of in situ versus ex situ perfusion on micro circulation in liver procurement--an experimental trial in a porcine model.

2012

The Achilles heel of liver transplantation remains the biliary system. The crucial step for liver preservation is effective rinsing and perfusion of the peribiliary plexus (PBP). Due to the physiology of the vascular tree, it seems almost impossible to achieve the necessary physiologic ranges of pressure and flow by the in situ perfusion technique. We investigated the role of additional ex situ perfusion via the hepatic artery in this animal model.Fifteen German Landrace pigs underwent standardized multiorgan procurement. In situ perfusion and additional ex situ perfusion were performed consecutively. Meanwhile the external pressure applied to the perfusion system was increased stepwise. To…

In situPathologymedicine.medical_specialtyTissue and Organ ProcurementSwinemedicine.medical_treatmentLiver transplantationMicrocirculationAnimal modelHepatic ArteryMedicineAnimalsLiver preservationTransplantationFrozen section procedurebusiness.industryMicrocirculationLiver TransplantationPerfusionmedicine.anatomical_structureModels AnimalSurgeryNuclear medicinebusinessPerfusionArteryTransplantation proceedings
researchProduct

Comparison of two different techniques of reperfusion in adult orthotopic liver transplantation

2006

: The aim of this study was to determine the impact of two reperfusion techniques on the peri-operative hemodynamic changes and early post-operative graft function of adult patients undergoing orthotopic liver transplantation. Material and methods: From June 2003 to May 2004, 50 consecutive liver transplants were performed and divided into two groups: group A, 25 patients, portal vein flush with 500 cm3 of Ringer's lactate without vena caval venting. Group B, 25 patients, vena caval venting with no portal vein flush. Donor and recipient characteristics were similar in both groups. Sixty-four different parameters were analyzed, and Pearson's χ2 test and t-test were used for statistical analy…

InferiorAdultMalemedicine.medical_specialtyOrthotopic liver transplantation; Post-reperfusion syndrome; Reperfusion technique; Adolescent; Adult; Aged; Aged 80 and over; Child; Female; Humans; Liver Transplantation; Male; Middle Aged; Portal Vein; Reperfusion; Tissue Donors; Vena Cava Inferior; TransplantationVena CavaAdolescentOrthotopic liver transplantationmedicine.medical_treatmentPortal veinHemodynamicsPost-reperfusion syndromeVena Cava InferiorLiver transplantationVena caval80 and overmedicineHumansStatistical analysisChildAgedAged 80 and overReperfusion techniqueTransplantationAdult patientsPortal Veinbusiness.industrySignificant differenceMiddle AgedSettore ING-IND/35 - Ingegneria Economico-GestionaleTissue DonorsLiver TransplantationSurgerySettore MED/18 - Chirurgia GeneraleReperfusioncardiovascular systemFemaleOrthotopic liver transplantationbusinessClinical Transplantation
researchProduct

ERAS Protocol for Perioperative Care of Patients Treated with Laparoscopic Nonanatomic Liver Resection for Hepatocellular Carcinoma: The ISMETT Exper…

2020

Background: Liver resection (LR) remains the best therapeutic option for patients with early-stage hepatocellular carcinoma (HCC) with preserved hepatic function and who are not eligible for liver transplantation. After its inception, the enhanced recovery after surgery (ERAS) protocol was widely used for treating patients with liver cancer, although there are still no clear indications for improving upon it in both open and laparoscopic surgery. Objective: This study aims to describe our institute's experience in the application of the ERAS protocol in a cohort of HCC patients, and to explore possible factors that could have an impact on postoperative outcomes. Materials and Methods: We re…

Laparoscopic surgeryLiver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentLiver transplantation03 medical and health sciences0302 clinical medicinePostoperative ComplicationsmedicineHepatectomyHumansERASPostoperative PeriodAgedRetrospective StudiesAnalgesicsbusiness.industryNutritional SupportLiver NeoplasmsRetrospective cohort studyPerioperativehepatocellular carcinomalaparoscopic liver resectionLength of StayMiddle Agedmedicine.diseaseSurgery030220 oncology & carcinogenesisHepatocellular carcinomaoutcome030211 gastroenterology & hepatologySurgeryFemaleLaparoscopyHepatectomybusinessLiver cancerEnhanced Recovery After Surgery
researchProduct

Inflammasomes in Liver Fibrosis

2017

AbstractCell death and inflammation are two central elements in the development of liver fibrosis. Inflammasomes are intracellular multiprotein complexes expressed in both hepatocytes and nonparenchymal cells in the liver that are key regulators of inflammation and cell fate. They respond to cellular danger signals by activating caspase 1, releasing the proinflammatory cytokines IL-1β and IL-18, as well as initiating a novel pathway of programmed cell death termed “pyroptosis.” These processes can initiate and perpetuate an abnormal wound-healing response with the principle cellular target being the activation of hepatic stellate cells. From the various inflammasomes, the NLRP3 inflammasome…

Liver Cirrhosis0301 basic medicinemedicine.medical_treatmentAnti-Inflammatory AgentsCaspase 1BiologyLiver transplantationProinflammatory cytokine03 medical and health sciencesLiver diseaseFibrosisNLR Family Pyrin Domain-Containing 3 ProteinPyroptosismedicineAlarminsAnimalsHumansHepatologyPyroptosisInflammasomemedicine.disease030104 developmental biologyReceptors Pattern RecognitionImmunologyHepatic stellate cellInflammation MediatorsSignal Transductionmedicine.drugSeminars in Liver Disease
researchProduct

Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.

2010

It is increasingly clear that a tailored therapeutic approach to patients with hepatitis C virus infection is needed. Success rates in difficult to treat and low-responsive hepatitis C virus patients are not completely satisfactory, and there is the need to optimise treatment duration and intensity in patients with the highest likelihood of response. In addition, the management of special patient categories originally excluded from phase III registration trials needs to be critically re-evaluated. This article reports the recommendations for the treatment of hepatitis C virus infection on an individual basis, drafted by experts of three scientific societies.

Liver CirrhosisANTIVIRAL TREATMENTHuman immunodeficiency virus (HIV)HIV InfectionsHepacivirusANTIVIRAL THERAPY; PEGYLATED INTERFERON-ALPHA-2B; LIVER-TRANSPLANTATION; PEGINTERFERON ALPHA-2A; HIV-INFECTED PATIENTS; VIRUS-COINFECTED PATIENTS; RAPID VIROLOGICAL RESPONSEAntiviral therapymedicine.disease_causeGastroenterologyPolyethylene GlycolsHBVguidelinesAcute hepatitisChronic hepatitisSettore MED/12 - Gastroenterologialiver transplantationGastroenterologyAntiviral therapyHepatitis CVIRUS-COINFECTED PATIENTSLIVER-TRANSPLANTATIONHepatitis CRecombinant Proteinsacute hepatitis; antiviral therapy; chronic hepatitis; cirrhosis; elderly patients; hbv; hcv; hdv; hiv; liver transplantationCLINICAL PRACTICE GUIDELINESCirrhosisHCVDrug Therapy CombinationAntiviral therapy Acute hepatitis Chronic hepatitisCirrhosis Elderly patients HBV HCV HDV HIV Liver transplantationElderly patientAcute hepatitiAcute hepatitismedicine.medical_specialtyGenotypePEGINTERFERON ALPHA-2AAlpha interferonHIV-INFECTED PATIENTSInterferon alpha-2CHRONIC HEPATITIS CAntiviral AgentsHepatitis B ChronicChronic hepatitisInternal medicineHDVDrug Resistance ViralRibavirinmedicineHumansPEGYLATED INTERFERON-ALPHA-2BCirrhosiHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAInterferon-alphaHIVHepatitis C Chronicmedicine.diseaseElderly patientsFamily medicineExpert opinionAntiviral therapy; Acute hepatitis; Chronic hepatitis; Cirrhosis; Elderly patients; HBV; HCV; HDV; HIV; liver transplantationChronic hepatitiRAPID VIROLOGICAL RESPONSEbusinessCHRONIC HEPATITIS C; ANTIVIRAL TREATMENT; CLINICAL PRACTICE GUIDELINES
researchProduct

From current status to optimization of HCV treatment: Recommendations from an expert panel

2016

Chronic hepatitis C virus (HCV) infection is a major public health problem at a global level, causing an enormous burden of hepatic and extra-hepatic morbidity and mortality. Treatment of chronic HCV (CHC) has been revolutionized in the last few years by the introduction of highly effective and well tolerated direct acting antiviral agents (DAAs) able to achieve >90% rates of sustained virological response (SVR) in many groups of patients, including those previously excluded from interferon-based regimens. For such reason interferon-free regimens are now the treatments of choice for all patients. Successful anti-HCV treatment can stop liver disease progression and can solve the HCV-relat…

Liver CirrhosisDirect-acting antiviral agentmedicine.medical_treatmentResistanceAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistance; Antiviral Agents; Carcinoma Hepatocellular; Coinfection; Drug Therapy Combination; HIV Infections; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Liver Neoplasms; Practice Guidelines as Topic; Ribavirin; Societies Medical; Viral Load; Hepatology; GastroenterologyHIV InfectionsHepacivirusAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistance; Hepatology; GastroenterologyLiver transplantationAntiviral therapyLiver disease0302 clinical medicineHIV Infection030212 general & internal medicineChronicSocieties MedicalCoinfectionLiver NeoplasmsGastroenterologyHepatitis CViral LoadSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CItalyCirrhosisLiver NeoplasmCombinationPractice Guidelines as TopicHCV030211 gastroenterology & hepatologyDrug Therapy CombinationViral loadHumanAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistancemedicine.medical_specialtyCarcinoma HepatocellularLiver CirrhosiAlpha interferonAntiviral therapy; Cirrhosis; Direct-acting antiviral agents; HCV; Hepatitis C; Liver transplantation; Resistance; Antiviral Agents; Carcinoma Hepatocellular; Coinfection; Drug Therapy Combination; HIV Infections; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Liver Cirrhosis; Liver Neoplasms; Practice Guidelines as Topic; Ribavirin; Societies Medical; Viral LoadAntiviral Agents03 medical and health sciencesDrug TherapyMedicalInternal medicineRibavirinmedicineHumansIntensive care medicineAntiviral AgentCirrhosiHepaciviruLiver transplantationHepatologybusiness.industryPublic healthCarcinomaInterferon-alphaHepatocellularHepatologyHepatitis C Chronicmedicine.diseaseSurgeryPosition paperDirect-acting antiviral agentsSocietiesbusiness
researchProduct

Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation.

2022

The rising tide of non-alcoholic fatty liver disease (NAFLD) associated with the obesity epidemic is a major health concern worldwide. NAFLD - specifically its more advanced form, non-alcoholic steatohepatitis (NASH)-related cirrhosis - is now the fastest growing indication for liver transplantation in the USA and Europe. Although the short-term and mid-term overall survival rates of patients who receive a liver transplant for NASH-related cirrhosis are essentially similar to those of patients who receive a transplant for other liver indications, recipients with NASH-related cirrhosis have an increased risk of waiting-list mortality and of developing recurrent liver disease and cardiometabo…

Liver CirrhosisEndocrinologyCardiovascular DiseasesNon-alcoholic Fatty Liver DiseasecirrhosisNAFLDEndocrinology Diabetes and MetabolismNASHreviewNASH post-liver transplantation cirrhosis reviewHumanspost-liver transplantationLiver TransplantationNature reviews. Endocrinology
researchProduct

Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the…

2020

Abstract Background The COVID-19 pandemic had a huge impact on national and regional health systems. The impact of SARS-CoV-2 on the quality of care for patients with liver disease is still unknown. Aims The Italian Association for the Study of the Liver (AISF) conducted a survey to assess the impact of SARS-CoV-2 on hepatology units activities in Italy. Methods A prospective web-based survey was proposed to all AISF active members. The survey was available online from April 8 2020, to May 3 2020, (lockdown phase in Italy). Results 194 AISF members answered the questionnaire, most of whom were specialists in Gastroenterology (41%) or Internal Medicine (28%), and worked in Northern Italy (51…

Liver CirrhosisLiver disease0302 clinical medicineSurveys and QuestionnairesPandemicAmbulatory CareMass ScreeningParacentesisViralChronicLiver DiseasesLiver NeoplasmsGastroenterologyHepatology Covid-19 SARS COV-2Hepatitis BHepatitis CHospitalizationCovid-19; Hepatology; SARS COV-2Italy030220 oncology & carcinogenesis030211 gastroenterology & hepatologyCoronavirus Infectionsmedicine.medical_specialtyCarcinoma HepatocellularCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralEsophageal and Gastric VaricesAntiviral AgentsArticle03 medical and health sciencesBetacoronavirusHepatitis B ChronicInternal medicinemedicineHumansPandemicsMass screeningQuality of Health CareHepatologybusiness.industrySARS-CoV-2SARS COV-2CarcinomaOutbreakCOVID-19HepatocellularPneumoniaHepatitis C ChronicHepatologymedicine.diseaseNorthern italyLiver TransplantationEmergency medicineChronic DiseaseCovid-19; Hepatology; SARS COV-2; Ambulatory Care; Antiviral Agents; Betacoronavirus; COVID-19; Carcinoma Hepatocellular; Chronic Disease; Coronavirus Infections; Esophageal and Gastric Varices; Gastroenterology; Hepatitis B Chronic; Hepatitis C Chronic; Hospitalization; Humans; Italy; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Liver Transplantation; Mass Screening; Pandemics; Paracentesis; Pneumonia Viral; Quality of Health Care; SARS-CoV-2; Surveys and Questionnairesbusiness
researchProduct

Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis.

2019

Abstract Introduction and objectives Non-alcoholic steatohepatitis (NASH) indication of liver transplant (LT) has increased recently, whereas alcoholic cirrhosis remains a major indication for LT. To characterize NASH-related cases and to compare the post-transplant outcome of these two conditions represents our major objective. Material and methods Patients undergoing LT for NASH between 1997 and 2016 were retrieved. Those transplanted between 1997 and 2006 were compared to an “age and LT date” matched group of patients transplanted for alcoholic cirrhosis (ratio 1:2). Baseline features and medium-term outcome measures were compared. Results Of 1986 LT performed between 1997 and 2016, 40 (…

Liver CirrhosisMaleAlcoholic liver diseaseCirrhosisHepatocellular carcinomamedicine.medical_treatmentSpecialties of internal medicineLiver transplantationGastroenterologyCohort Studies0302 clinical medicinePostoperative ComplicationsLiver Cirrhosis AlcoholicNon-alcoholic Fatty Liver DiseaseCause of DeathHyperuricemiaRenal InsufficiencyCardiovascular risk factorsIncidence (epidemiology)Liver NeoplasmsGeneral MedicineMiddle AgedSurvival RateTreatment OutcomeRC581-951Cardiovascular Diseases030220 oncology & carcinogenesisHepatocellular carcinomaHypertension030211 gastroenterology & hepatologyFemaleAlcoholAdultmedicine.medical_specialtyCarcinoma HepatocellularHyperuricemia03 medical and health sciencesYoung AdultInternal medicinemedicineDiabetes MellitusHumansObesityAgedDyslipidemiasRetrospective StudiesHepatologybusiness.industrynutritional and metabolic diseasesOverweightmedicine.diseasedigestive system diseasesLiver TransplantationSpainSteatohepatitisNeoplasm Recurrence LocalbusinessDyslipidemiaAnnals of hepatology
researchProduct

Genetic similarity of hepatitis C virus and fibrosis progression in chronic and recurrent infection after liver transplantation

2006

SUMMARY. The effect of hepatitis C virus (HCV) genetic heterogeneity on clinical features of post-transplantation hepatitis C is controversial. Different regions of the HCV genome have been associated with apoptosis, fibrosis, and other pathways leading to liver damage in chronic HCV infection. Besides, differences in immunodominant regions, such as NS3, may influence HCV-specific immune responses and disease outcome. In the liver transplant setting, a recent study has reported a positive association between HCV-1b Core region genetic relatedness 5-year post-transplantation and histological severity of recurrent hepatitis C. We have compared nucleotide sequences of HCV Core, NS3 and NS5b re…

Liver CirrhosisMaleCirrhosisBiopsyHepatitis C virusmedicine.medical_treatmentGenome ViralHepacivirusViral Nonstructural ProteinsLiver transplantationBiologymedicine.disease_causeVirusCohort StudiesSpecies SpecificityRecurrenceFibrosisVirologymedicineHumansHepatologySequence Analysis RNAGenetic heterogeneityViral Core Proteinsvirus diseasesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseasedigestive system diseasesLiver TransplantationChronic infectionInfectious DiseasesLiverSpainImmunologyDisease ProgressionFemaleJournal of Viral Hepatitis
researchProduct